

# Acute Myeloid Leukemia (AML)

## Understanding acute myeloid leukemia (AML)

AML is an aggressive cancer of the blood and bone marrow.<sup>1</sup> AML prevents white blood cells from maturing, causing an accumulation of immature “blasts” (leukemic cells) which do not allow room for normal, healthy cells to grow.<sup>1</sup> These leukemic cells can spread outside of the bloodstream and into other areas of the body, such as the central nervous system, skin and gums.<sup>1</sup> As the leukemia spreads, infection, anemia or easy bleeding may occur due to a diminished number of healthy blood cells.<sup>1</sup> In some cases, early signs of AML are vague and may be confused with those of other common diseases.<sup>1</sup>

AML is the most common form of acute leukemia in adults and is also responsible for the largest number of leukemia annual deaths.<sup>2</sup> AML gets worse quickly if it is not treated; therefore it is important to begin treatment as soon as possible.<sup>1</sup> Many patients may feel overwhelmed as they get rushed into therapy, leaving little time to prepare (i.e. understand the diagnosis, notify work, etc.).<sup>3</sup>

## Mutations in AML

Mutations in specific genes are found in many cases of AML and can be identified using genetic tests.<sup>4</sup> The results of the tests can be used for diagnosis and patient risk stratification.<sup>4</sup> While some mutations are associated with favorable outcomes, others are more aggressive and are associated with a poor prognosis.<sup>4</sup> The most common mutations found in AML include FLT3, NPM1, DNMT3A, NRAS, CEBRA, TET2, WT1, IDH2, IDH1 and KIT.<sup>5</sup> These genetic mutations affect the growth and development of cells, leading to cancerous cell formation.

## Patient journey

An AML diagnosis is made based on:<sup>6</sup>

- Medical history and physical examination
- Complete blood count
- A sample of cells taken from the bone marrow (bone marrow biopsy) to look at the types of cells present and for any signs of leukemia
- Genetic tests

Once diagnosis is confirmed, a treatment regimen will be started to reduce the number of cancer cells.<sup>6</sup> Treatment should be started as soon as possible.<sup>6</sup> Due to intense treatment resulting in a compromised immune system, it is recommended to stay in hospital for the first few weeks.<sup>7</sup> Bone marrow and blood samples are taken regularly to determine if the treatment is working or if more needs to be given.<sup>2</sup> If the cancer returns and the patient relapses, several options are available, including restarting treatment or taking part in a clinical trial.<sup>2</sup>

Prognosis and survival rate may depend on numerous factors including age, location of disease, recurrence

status, etc.<sup>1</sup>

## Questions to ask your doctor

- What type of AML do I have?
- What will happen next?
- What tests will I have done?
- How and when will I get the results?
- What is my prognosis?
- What are the risks associated with my treatment?
- Will I need a stem cell transplant?
- If my disease stops responding to treatment, what are my options?
- Should I consider clinical trials?
- As a caregiver, how can I provide support?
- Where can I find AML resources and support?

## Additional resources

- [AML Interactive Guide](#)
- [AML Infographic](#)

### References

1. NIH NCI. Available at: <http://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq>. Accessed January 5, 2017.
2. NCCN Guidelines Version 2.2016 Acute Myeloid Leukemia Available at: [http://www.nccn.org/professionals/physician\\_gls/pdf/aml.pdf](http://www.nccn.org/professionals/physician_gls/pdf/aml.pdf). Accessed January 5, 2017.
3. LeBlanc TW, et al. Patient Experiences of Acute Myeloid Leukemia (AML): A Qualitative Study about Diagnosis, Illness Understanding, and Treatment Decision-Making. *Blood*. 2015. 126:2119.
4. Hatzimichael E. et al. Gene mutations and molecularly targeted therapies in acute myeloid leukemia: *American Journal of Blood Research*. 2013;3(1):29-51.
5. Patel JP et al. Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia. *The New England Journal of Medicine*. 2012; 366(12):1079-89.
6. National Institute of Health (NIH) National Cancer Institute (NCI). Adult Acute Myeloid Leukemia Treatment (PDQ®) <http://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq>. Accessed January 20, 2017.
7. Cancer.net. Leukemia - Acute Myeloid - AML: Treatment Options. <http://www.cancer.net/cancer-types/leukemia-acute-myeloid-aml/treatment-....>. Accessed January 20, 2017.

---

**Source URL:** <https://prod1.novartis.com/diseases/acute-myeloid-leukemia-aml>

### List of links present in page

1. <https://prod1.novartis.com/diseases/acute-myeloid-leukemia-aml>
2. [https://prod1.novartis.com/sites/novartis\\_com/files/acute-myeloid-leukemia-aml-interactive-guide.pdf](https://prod1.novartis.com/sites/novartis_com/files/acute-myeloid-leukemia-aml-interactive-guide.pdf)
3. [https://prod1.novartis.com/sites/novartis\\_com/files/acute-myeloid-leukemia-aml-infographic.pdf](https://prod1.novartis.com/sites/novartis_com/files/acute-myeloid-leukemia-aml-infographic.pdf)
4. <http://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq>
5. [https://www.nccn.org/login?ReturnURL=https%3A//www.nccn.org/professionals/physician\\_gls/pdf/aml.pdf](https://www.nccn.org/login?ReturnURL=https%3A//www.nccn.org/professionals/physician_gls/pdf/aml.pdf)
6. <http://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq>
7. <https://www.cancer.net/cancer-types/leukemia-acute-myeloid-aml/treatment-options>

